<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dysregulated TGF-β signaling is associated with a spectrum of osseous defects as seen in Loeys-Dietz <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">syndrome, Marfan</z:e> syndrome, and Camurati-Engelmann disease </plain></SENT>
<SENT sid="1" pm="."><plain>Intriguingly, <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1 (NF1) patients exhibit many of these characteristic skeletal features including <z:hpo ids='HP_0002751'>kyphoscoliosis</z:hpo>, <z:hpo ids='HP_0000939'>osteoporosis</z:hpo>, tibial <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and pseudarthrosis; however, the molecular mechanisms mediating these phenotypes remain unclear </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we provide genetic and pharmacologic evidence that <z:mp ids='MP_0001399'>hyperactive</z:mp> TGF-β1 signaling pivotally underpins osseous defects in Nf1(flox/-) ;Col2.3Cre mice, a model which closely recapitulates the <z:hpo ids='HP_0000924'>skeletal abnormalities</z:hpo> found in the human disease </plain></SENT>
<SENT sid="3" pm="."><plain>Compared to controls, we show that serum TGF-β1 levels are 5-6 fold increased both in Nf1(flox/-) ;Col2.3Cre mice and in a cohort of NF1 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Nf1 deficient osteoblasts, the principal source of TGF-β1 in bone, overexpress TGF-β1 in a gene dosage dependent fashion </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, Nf1 deficient osteoblasts and osteoclasts are <z:mp ids='MP_0001400'>hyperresponsive</z:mp> to TGF-β1 stimulation, potentiating osteoclast bone resorptive activity while inhibiting osteoblast differentiation </plain></SENT>
<SENT sid="6" pm="."><plain>These <z:mp ids='MP_0005384'>cellular phenotypes</z:mp> are further accompanied by p21-Ras dependent hyperactivation of the canonical TGF-β1-Smad pathway </plain></SENT>
<SENT sid="7" pm="."><plain>Re-expression of the human, full-length neurofibromin GTPase-activating protein (GAP) related domain (NF1 GRD) in primary Nf1 deficient osteoblast progenitors, attenuated TGF-β1 expression levels and reduced Smad phosphorylation in response to TGF-β1 stimulation </plain></SENT>
<SENT sid="8" pm="."><plain>As an in vivo proof of principle, we demonstrate that administration of the TβRI kinase inhibitor, SD-208, can rescue bone mass deficits and prevent tibial fracture non-union in Nf1(flox/-) ;Col2.3Cre mice </plain></SENT>
<SENT sid="9" pm="."><plain>In sum, these data demonstrate a pivotal role for <z:mp ids='MP_0001399'>hyperactive</z:mp> TGF-β1 signaling in the pathogenesis of NF1 associated <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> and pseudarthrosis, thus implicating the TGF-β signaling pathway as a potential therapeutic target in the treatment of NF1 osseous defects which are refractory to current therapies </plain></SENT>
</text></document>